Health
Bristol Myers Squibb to Present Data at ASCO® 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline
PRINCETON, N.J., May 22, 2025--BMS to Present Data at ASCO® 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline
About this update from Bristol-myers Squibb Company
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1497,"height":206,"url":"https://media.zenfs.com/en/business-wire.com/05a924c47e4e1f9fe7c424bde2541423"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/2jShq1pfQddr_dYNT0lM4Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTEzMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/05a924c47e4e1f9fe7c424bde2541423","width":960,"height":132},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/pAr5NjbZrY_oRGfJu8sTnA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0zMzA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/05a924c47e4e1f9fe7c424bde2541423","width":1200,"height":165}},"lazy":false},{"type":"text","content":"PRINCETON, N.J., May 22, 2025--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its oncology portfolio and pipeline at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting to be held May 30-June 3 in Chicago, Illinois. Data from more than 80 company-sponsored studies, investigator-sponsored studies, and collaborations showcase results spanning more than 20 cancer types.","length":438,"tagName":"p"},{"type":"text","content":""Bristol Myers Squibb is advancing novel approaches to address high unmet needs in cancer and at this year’s ASCO meeting, we are highlighting data across a range of assets, including our targeted therapy pipeline, and new data that support the use of our portfolio in earlier lines of treatment, enhancing or improving patient outcomes," said Samit Hirawat, M.D., executive vice president, chief medical officer, head of development, Bristol Myers Squibb. "We are a company that has redefined the cancer care landscape and we are leveraging our deep expertise, combined with innovative technologies and modalities, to deliver new medicines and breakthrough advances for patients."","length":701,"tagName":"p"},{"type":"text","content":"Key data to be presented by Bristol Myers Squibb and its collaborators at ASCO include:","length":87,"tagName":"p"},{"type":"text","content":"Highlighting our leading portfolio with long-term survival data and intervention earlier in the treatment of disease","length":116,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Results from the independent ...